NCT04905914
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with known unstable CNS metastases – see trial for details; Patients with prior radiotherapy at the target lesion unless there is evidence of disease progression
https://ClinicalTrials.gov/show/NCT04905914